Most Read Articles
Jairia Dela Cruz, 19 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
28 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
7 days ago
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
3 days ago
Mesalazine is not superior to placebo in terms of preventing recurrence in patients with diverticulitis, according to data from two phase III trials.

FLD may increase risk of atherosclerotic progression in healthy obese individuals

2 months ago
73% of workers aged above 40 were also found to be overweight or obese.

Despite their healthy metabolic profile, metabolically healthy obese (MHO) individuals with fatty liver disease (FLD) are at a higher risk of atherosclerotic progression, a new study shows.

The study involved 1,240 patients (mean age 54.2±7.4 years) who underwent coronary artery calcification (CAC) score measurements during routine check-ups. Those with histories of cardiovascular diseases, taking statins, with hepatocellular carcinoma and who had received liver transplants were excluded.

CAC scores were measured using coronary computed tomography angiography (CCTA) and hepatic ultrasounds. Hepatic ultrasonography was used to potentially diagnose FLD.

Of all participants, 22.7 percent (n=282) had the MHO phenotype. There were more males in the MHO group than in the MH nonobese (MHNO) group. Moreover, individuals in the MHO group had higher levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG) and fasting plasma glucose (FPG).

CAC progression was observed in 25.2 percent (n=312) of participants over the median follow-up period of 2.9 (0.8 to 7.0) years. The metabolically unhealthy obese group (MUO) had the highest proportion of CAC progression (32.3 percent), followed by MHO (28.0 percent), MU nonobese (MUNO; 23.1 percent) and MHNO (19.2 percent).

MHO individuals had an increased risk of CAC progression (unadjusted odds ratio [OR], 1.63; 95 percent CI, 1.15 to 2.32) compared to MHNO individuals. After controlling for confounders, only the MUO had a significantly greater risk of CAC progression (adjusted OR, 1.71; 1.10 to 2.65).

Finally, CAC progression was significantly associated with MHO individuals with FLD at baseline (adjusted OR, 2.37; 1.34 to 4.16) relative to MHNO individuals without baseline FLD. By comparison, MHO individuals without baseline FLD showed no significant association to CAC progression (adjusted OR, 1.26; 0.71 to 2.24).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 19 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
28 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
7 days ago
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
3 days ago
Mesalazine is not superior to placebo in terms of preventing recurrence in patients with diverticulitis, according to data from two phase III trials.